Video

Spesolimab for Treatment of GPP

Author(s):

Raj Chovatiya, MD, PhD,Boni Elewski, MD

Experts discuss spesolimab, an IL-36 inhibitor, that was recently FDA approved for treatment of GPP.

Related Videos
Andrea Murina, MD: Drug Pipeline for Hidradenitis Suppurativa
Omega-3 Supplements for Rosacea and Other Tips for Dermatologists, with Andrea Murina, MD
Methods to Manage Psoriasis Using Oral Therapies, with Andrea Murina, MD
2 Additional Clinical Pearls for Dermatologists, with Eingun James Song, MD
2 Helpful Clinical Tips for Dermatologists, with Eingun James Song, MD
What Are Some Other Methods To Manage Skin Cancer Outside of Biopsies?
New ‘Level Up’ Data on Upadacitinib (Rinvoq) for Atopic Dermatitis, with Christopher Bunick, MD, PhD
Christopher Bunick, MD, PhD: Facts About Systemic Therapies’ Safety, Mechanism of Action
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
Related Content
Dermatology Month in Review | November 2024
December 3rd 2024

Dermatology Month in Review | November 2024

Tim Smith
The Medical Sisterhood: Role Models and Mentorship, with Susan Taylor, MD, and Linda Stein Gold, MD
November 18th 2024

The Medical Sisterhood: Role Models and Mentorship, with Susan Taylor, MD, and Linda Stein Gold, MD

Mona Shahriari, MD, FAAD Linda Stein Gold, MD Susan Taylor, MD
Link Identified Between Obesity, Inflammatory Skin Diseases Such as Psoriasis
November 26th 2024

Link Identified Between Obesity, Inflammatory Skin Diseases Such as Psoriasis

Tim Smith
Default thumbnail for The Medical Sisterhood with Mona Shahriari, MD
October 18th 2024

The Medical Sisterhood: Motherhood in Medicine, with Alexandra Golant, MD

Mona Shahriari, MD, FAAD
Study Finds Chronic Psychological Stress Triggers Skin Aging
November 21st 2024

Study Finds Chronic Psychological Stress Triggers Skin Aging

Tim Smith
FDA Approves Bimekizumab for Adults with Hidradenitis Suppurativa
November 20th 2024

FDA Approves Bimekizumab for Adults with Hidradenitis Suppurativa

Tim Smith
© 2024 MJH Life Sciences

All rights reserved.